Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference
November 12, 2026
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
October 30, 2026
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
October 9, 2026
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
October 8, 2026
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
September 3, 2026
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
August 12, 2026
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
August 6, 2026
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
July 30, 2026
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
July 21, 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
July 7, 2026
1
2
Next Page
→